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9 Abstract
10 Introduction Poor adherence to anti-hypertensive treat-
11 ment signiﬁcantly contributes to the failure to achieve ef-
12 fective-controlled blood pressure in patients with
13 hypertension.
14 Aim The aim of this study was to convert the original
15 English version of Medication Adherence Self-efﬁcacy
16 Scale (MASES) into a Persian version for clinical appli-
17 cation in hypertensive patients.
18 Methods The backward–forward translation method was
19 used to produce the Persian version of the questionnaire.
20 Then the internal consistency was assessed using Cron-
21 bach’s alpha. Exploratory Factor Analysis was applied to
22 extract components of the questionnaire. Correlation be-
23 tween blood pressures and drug adherence using MASES
24 was drawn in hypertensive patients.
25 Results Cronbach’s alpha coefﬁcient of the Persian ver-
26 sion of MASES was[0.92, suggesting that it can yield
27 consistent results. Exploratory Factor Analysis suggested
28 an unidimensionality of the scale. Patients with
29uncontrolled hypertension showed poor adherence to hy-
30pertensive medications, therefore had signiﬁcant lower
31self-efﬁcacy scores than those with well-controlled blood
32pressure by medication.
33Conclusion The Persian version of MASES is valid and
34reliable to assess self-efﬁcacy of anti-hypertension
35medication adherence in hypertensive patient, which is
36helpful to improve medication compliance in such patients
37in order to achieve better blood pressure control.
38
39Keyword Hypertension  Blood pressure control 
40Self-efﬁcacy
411 Introduction
42Hypertension is one of the major causes of cerebrovascular
43and cardiovascular diseases and related mobility and
44motility. Hypertension is usually a chronic asymptomatic
45condition. It is estimated that worldwide about 60 % of the
46adult population will develop hypertension in year 2025.
47Compared to the developed countries, the risk of hyper-
48tension in the developing countries has almost been dou-
49bled, including Iran [1]. Uncontrolled hypertension is
50deﬁned as systolic blood pressure greater than 140 mmHg
51or diastolic blood pressure greater than 90 mmHg. How-
52ever, according to the latest recommendation of European
53Society of Hypertension, an ideal target blood pressure is
54less than 140/85 mmHg [2, 3]. In most cases, lifestyle
55modiﬁcation and anti-hypertensive drugs are necessary to
56maintain an ideal blood pressure in order to reduce the risk
57of developing cerebrovascular and cardiovascular diseases
58[4].
59Only a third of the patients with hypertension have
60adequate control over their blood pressure levels [5].
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61 Despite active and intensive drug treatment and increased
62 awareness, the blood pressure in hypertensive patients is
63 still poorly controlled in many countries [6]. Poor adher-
64 ence to anti-hypertensive treatment has been shown to
65 signiﬁcantly contribute to the failure to achieve the goals of
66 blood pressure management in the Seventh Report of the
67 Joint National Committee on Prevention, Detection,
68 Evaluation and Treatment of High Blood Pressure, which is
69 unfortunately a global phenomenon [7]. Even with the
70 access to effective anti-hypertensive medications, more
71 than half of the patients spontaneously stopped their
72 medication within the ﬁrst year after the treatment initiated.
73 Moreover, among the patients who have long-term hyper-
74 tension, 50 % of them received more than 80 % of total
75 prescribed medications [8]. As a result of poor adherence to
76 anti-hypertensive medications, approximately 75 % of
77 hypertensive patients cannot achieve good control of their
78 blood pressure [8].
79 Medication-taking behavior is a complex interaction
80 between the biological, psychological and social factors
81 [9]. There are several theories to explain the adherence
82 behavior in hypertensive patients [10, 11]. The theory that
83 is well regarded is the self-efﬁcacy theory. Self-efﬁcacy is
84 deﬁned as the perception of one’s ability to complete a
85 take, a goal, or a speciﬁc challenge [12]. Self-efﬁcacy has
86 been considered as the most prominent predictor for health
87 related behavioral change, such as adherence to medica-
88 tions in patients with chronic diseases [9]. Hypertensive
89 patients with high levels of self-efﬁcacy are more likely to
90 feel conﬁdent to adhere to their medications [9, 13].
91 Self-efﬁcacy is a type of self-assessment and self-con-
92 ﬁdence to perform a speciﬁc task, related to this study, the
93 adherence to hypertensive medications. According to
94 Bandura, it is one of the most important psychological
95 factors that impact on medication adherence [14]. There
96 are increased evidence on the effects of social learning,
97 speciﬁcally self-efﬁcacy, on the improvement of adherence
98 over the past two decades [13]. Self-efﬁcacy has been
99 shown to be able to predict medication adherence in indi-
100 viduals diagnosed with chronic diseases [9]. McCann and
101 colleagues considered self-efﬁcacy as a ‘‘cornerstone of
102 medication adherence’’ [15]. While there are discrepancy
103 in the speciﬁc types of self-efﬁcacy for different treat-
104 ments, domestic speciﬁc self-efﬁcacy is the form that im-
105 pacts on the treatment process and outcome [16].
106 Therefore, Ogedegbe and colleagues developed the
107 Medication Adherence Self-Efﬁcacy Scale (MASES) to
108 measure and identify situations in which patients expressed
109 concerns about self-efﬁcacy in adherence to prescribed
110 medications [9]. It is designed to evaluate those who have
111 struggled with blood pressure controls due to poor adher-
112 ence to prescribed antihypertensive medications. The de-
113 velopment of the MASE was based on the results from
114open-ended interviews with 106 patients on their experi-
115ence with anti-hypertensive medications. Responses were
116divided into nine qualitative categories with 43 questions to
117cover the barriers and facilitators to medication adherence.
118MASES can also be used as a research tool to assess the
119effectiveness of a behavioral intervention program to en-
120hance patients’ self-efﬁcacy [9, 17, 18].
121Several studies have investigated the medication com-
122pliance among different cohorts of patients in Iran; how-
123ever, none of these studies have assessed the medication
124adherence using MASES, nor in hypertensive patients with
125uncontrolled blood pressure. Thus, to assess the compli-
126ance of anti-hypertensive medication in Iranian patients
127with hypertension toward, we need a tool that is compatible
128with the cultural background. Therefore, this study aimed
129to, (1) translate the English version of Ogedegbe’s MASE
130into a Persian version, and; (2) examine the reliability and
131validity in patients with hypertension in Iran.
1322 Material and Methods
1332.1 Translation of the English Version
134into a Persian Version
135An agreement to translate the original MASE questionnaire
136was obtained by the authors. The ﬁrst stage of cultural
137adaptation was the translation of English questionnaire into
138Persian language, which was performed by two translators
139who are native English speakers and ﬂuent in Persian
140language (forward translation). One of the translators was
141informed of the objectives and concepts of the question-
142naire, whereas the other one was blind. This stage resulted
143in two translated versions. The differences between the two
144versions were compared and resolved between the two
145translators to yield the ﬁrst ﬁnal version [19].
146The English version of the MASES was again translated
147by a native Iranian linguist, who is ﬂuent in English and
148was unaware of the purpose of the questionnaire. The
149second translator is an Iranian cardiologist who was in-
150formed of the objectives of the current study. Both versions
151were assessed and consolidated between the researcher and
152the translator into a second ﬁnal version.
153Both ﬁnal versions were translated back into English by
154another two native Persian-speaking translators who are
155ﬂuent in English. These two translators did not receive any
156information on the concepts and purposes of the ques-
157tionnaire. This procedure is the quality control of the ac-
158curacy during the translation [19].
159Then, the Persian questionnaire was completed by 20
160hypertensive patients who were randomly selected from
161those who were excluded from the main study, in order to
162evaluate and validate the translated questionnaire. The data
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163 of questionnaires were collected anonymously by the au-
164 thors for later evaluation. The difﬁculty level of the Persian
165 questionnaire were then evaluated by a panel of experts in
166 psychology, cardiology, and general practice who are ex-
167 perienced in hypertension diagnosis and treatment, as well
168 as ﬁve hypertensive patients with different education
169 levels. Based on the assessment outcome, the questionnaire
170 was modiﬁed accordingly. In addition, lay language has
171 been used to replace the medical terminology. Subse-
172 quently, the ﬁnal version was again translated from Persian
173 into English by two bilingual translators independently,
174 who were unaware about the original English version of the
175 questionnaire. The discrepancies between the two trans-
176 lated versions were again consolidated and the ﬁnal version
177 of Persian MASE questionnaire was completed for a formal
178 assessment in hypertensive patients who met the selection
179 criteria.
180 2.2 The Evaluation of Validity and Reliability
181 The conﬁdence of the questionnaire was evaluated using
182 internal consistency and re-tests reliability. Cronbach’s
183 alpha coefﬁcient was used to assess the internal consis-
184 tency [20]. Interpretation of Item-total scale correlation
185 was used to assess the reliability of the questionnaire.
186 These coefﬁcients were only acceptable if the value of the
187 Self-efﬁcacy, the perception of one’s ability to complete a
188 task, a goal or a speciﬁc challenge (ICC) was greater than
189 0.3 and Cronbach’s alpha was equal to or greater than 0.7.
190 The exploratory Factor Analysis was used to assess the
191 factor structure of the questionnaire, and principal com-
192 ponent analysis was performed. Several tests were used to
193 assess the suitability of the respondent data before the
194 Factor Analysis, including Kaiser–Meyer–Olkin (KMO)
195 Measure of Sampling Adequacy, and Bartlett’s Test of
196 Sphericity. The KMO index is required when the case to
197 variation ratio is less than 1:5. The KMO index is ranged
198 from 0 to 1, with greater than 0.50 considered as suitable
199 for Factor Analysis. The Factor Analysis is only applicable
200 when the Bartlett’s Test of Sphericity is signiﬁcant
201 (P\ 0.05). In order to determine the group validity,
202 MASES survey results from patients with well controlled
203 blood pressure were compared with those with uncon-
204 trolled hypertension. It was hypothesized that patients with
205 well controlled blood pressure would have higher self-ef-
206 ﬁcacy scores than those with uncontrolled blood pressure.
207 Conﬁrmatory Factor Analysis was performed using the
208 statistical software LISREL 8.80. The Model Fitness was
209 evaluated using Chi-square (v
2), root mean square error of
210 approximation (RMSEA), Comparative Fit Index (CFI),
211 and Tucker–Lewis Index (TLI). Model modiﬁcations were
212 completed based on modiﬁcation index and the results of
213 reliability analysis. The criteria used to determine a good
214Model Fitness were a non-signiﬁcant Chi-square results,
215the ratio between Chi-square and its degrees of freedom
216\2.0, the value of TLI and CFI C0.95, and the value of
217RMSEA\0.06 [21, 22].
2182.3 The Use of Persian Version of MASES
219in Hypertensive Patients
220This study was conducted in the health centers afﬁliated to
221Qazvin University of Medical Sciences. This study was
222approved by the Human Research Ethics Committee of
223Qazvin University of Medical Sciences. All participants
224have signed a consent form.
225Based on the convenience sampling, 184 patients with
226hypertension who were referred to the health service cen-
227ters in Qazvin were recruited to participate in this study.
228Inclusive criteria were: 18 years and above, proﬁcient in
229Persian language (understanding Persian language), lit-
230eracy, using anti-hypertensive drugs for at least a year,
231volunteered to participate in the study, and have regular
232follow-up treatments for hypertension. The patients were
233excluded if they had physical or cognitive disorders or
234were unwilling to participate. The response rate was
23595.83 %. Eight patients who were eligible for the study
236were excluded due to unwillingness to participate. Statis-
237tical tests showed that there was no signiﬁcant difference
238between excluded and included patients in terms of socio-
239demographic variables.
240The MASES developed by Ogedegbe and colleagues [9]
241has been used to assess the self-efﬁcacy in the adherence to
242anti-hypertensive medications in patients with high mor-
243tality risk. The MASES is a patient-centered and self-ad-
244ministered questionnaire that consists of 26 items. The
245patient were asked to rate their conﬁdence of taking anti-
246hypertensive medications in different conditions using a
247three-point scale (1 = unsure, 2 = somewhat sure, and
2483 = very sure). This was performed by trained researchers
249when the patients were attended in the waiting room before
250their medical consultations. The total score of the 26 items
251was then summed up. The score is positively correlated
252with the level of self-efﬁcacy, with higher score reﬂecting
253higher self-efﬁcacy. Original factor structure showed the
254uni-dimensionality of the scale because the majority of
255items in this structure were loaded on Factor 1. In addition
256to the original MASES questions, several questions were
257designed to measure the general characteristics (socio-de-
258mographic) of the patient, including age, education, marital
259status, job status, socioeconomic status, and the number of
260medications used for controlling hypertension.
261Blood pressure was measured twice with an interval of
26210 min for each patient using an automated blood cuff by a
263general practitioner who was blind to the participants
264during the measurement. The average of the two
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265 measurements was used [23]. Patients were resting in a
266 quiet room for 10 min before the ﬁrst measurement and the
267 measurement was taken under the same condition [24].
268 Blood pressure was measured by a general practitioner who
269 was blind to the participants. P\ 0.05 was considered as
270 signiﬁcant for all the tests (SPSS 17, Chicago, IL, USA).
271 3 Results
272 It only took 5 min to complete the questionnaire and the
273 questions are easy to be understood by the patients.
274 Cronbach’s alpha coefﬁcient of the Persian version of the
275 MASES was[0.92, suggesting that this version can yield
276 consistent results over the time (25).
277 The general characteristics of the participants are shown
278 in Table 1. The age range of the participants was between
279 18 and 73 years old. Most participants in the study were
280married and their education levels were below tertiary
281degree. The majority of the patients were covered by the
282health insurance. Two thirds of the patients were unem-
283ployed, while most of the patients had fair or good eco-
284nomic status. The duration of the disease varies between
285patients, as well as the number of the medication (Table 1).
286Table 2 shows the self-efﬁcacy scores, item-to-total
287correlation, kappa coefﬁcients, and Cronbach’s alpha value
288among 184 patents. Mean self-efﬁcacy scores were ranged
289from 1.72 to 2.28 with the standard deviations ranged from
2900.51 to 0.81. For all items, kappa values were ranged from
2910.28 to 1. The kappa value was less than 0.4 for two items,
292while it was between 0.4–0.6 for 13 items. There are eleven
293items with kappa values greater than 0.6. The Cronbach’s
294alpha value was 0.91 for all 26 items. The item-to-total
295correlation coefﬁcients are between 0.248 and 0.685 for all
296items, which were all acceptable except for the Question 12
297which reads, ‘‘When you are afraid that the medications
298may affect your sexual performance’’. Although the item-
299total correlation value for this question was less than 0.3, it
300was not excluded from the current study. This is because
301that its Chronbach’s alpha value was 0.917 and the removal
302of this question did not change the internal consistency. In
303Addition, given that sexual disability is a barrier that is
304mentioned frequently by the patients, it was retained for its
305clinical importance, which has also been included in the
306original MASES by Ogedegbe and coworkers.
307Table 3 shows the factor loadings of each question,
308Eigen values, and the proportion of total variance against
309each factor. The KMO Measure value of the data was
3100.857, which suggests that there was sufﬁcient and high
311variability in the data to perform component analysis. The
312results of Bartlett Test of Sphericity (approximate v
2
313(325) = 1780.5, P\ 0.001) as well as KMO conﬁrmed the
314factorability of the data. An Exploratory Principal Com-
315ponents Factor Analysis performed on the 26 items in the
316MASES revealed a ﬁve-factor solution using the minimum
317Eigen value criteria (\1). These ﬁve factors contributed to
318about 67.8 % of the total variance (Table 3). Twenty out of
31926 items were loaded in Factor 1. Two items were loaded
320in Factors 2 and 3 and one item was loaded in Factors 4 and
3215. Six items (6, 15, 17, 19, 23 and 24) had substantial
322loadings on more than one factor (items with loadings
323C0.4). Factor loading of all the items were acceptable.
324The comparisons of Self-efﬁcacy scores between the
325patients with uncontrolled hypertension and those with
326well-controlled blood pressure are shown in Table 4. The
327former had signiﬁcantly higher systolic (P\ 0.05) and
328diastolic blood pressure (P\ 0.05) than the latter
329(Table 4). The average efﬁcacy score was higher in the
330patients with controlled blood pressure than those with
331uncontrolled hypertension (P\ 0.05), in 16 out of 26
332questions (Table 4).
Table 1 General characteristics of the sample (n = 184)
Characteristics Total Percentage








Never married 4 2.18
Education level
Primary school 84 45.66
High school 85 46.18
University degree 15 8.16
Type of insurance
Social welfare 98 53.26
Remedial service 58 31.53
Self-paid 22 11.95









Duration of hypertension (years) 6.00 ± 4.05
Number of medication 1.34 ± 0.85
Duration of treatment (years) 5.3 ± 3.64
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333 Hypertensive patients also showed lower medication
334 adherence self-efﬁcacy compared with normotensive indi-
335 viduals and pre-hypertensive patients (Hypertensive-Nor-
336 mal systolic, ZMWU = -2.236, P = 0.025, Hypertensive-
337 Normal systolic, ZMWU = -3.025, P = 0.002, Hyperten-
338 sive-Normal diastolic, ZMWU = -2.716, P = 0.007,
339 Hypertensive-Normal diastolic, ZMWU = -3.147, P =
340 0.002, (Table 5).
341 4 Discussion
342 This study modiﬁed the English version of MASES into
343 Persian language, according to the speciﬁcity of Iranian
344 culture. The validity and reliability were conﬁrmed in
345individuals with normal blood pressure and hypertensive
346patients with/without well controlled blood pressure, where
347patients with uncontrolled hypertension had signiﬁcantly
348lower self-efﬁcacy to adhere to anti-hypertensive medica-
349tion. The later clearly played a causal role in their uncon-
350trolled hypertension.
351The burden of chronic diseases, such as hypertension, is
352incasing in developing countries [25]. Poor self-efﬁcacy as
353a contributing factor to increased rate of uncontrolled hy-
354pertension shall receive more attention in these countries.
355Despite the fact that this study was conducted in a devel-
356oping country using a modiﬁed MASES on the adherence
357to hypertension treatment, the results are consistent with
358the studies using the original MASES in developed coun-
359tries, where it has been suggested that non-adherence to








How conﬁdent are you in taking your blood pressure medications?
1. When you are busy at home 1.92 ± 0.73 0.55 0.918 0.415
2. When you are at work/When you are busy with your daily
routines
1.87 ± 0.76 0.63 0.915 0.507
3. When there is no one to remind you 2.08 ± 0.71 0.48 0.915 0.506
4. When you worry about taking them for the rest of your life 1.92 ± 0.78 0.54 0.913 0.580
5. When they cause some side effects 1.78 ± 0.51 0.47 0.918 0.430
6. When they cost a lot of money 2.05 ± 0.75 0.46 0.914 0.535
7. When you come home late from work/when your work ﬁnishes
late
1.96 ± 0.66 0.72 0.914 0.569
8. When you do not have symptoms 1.82 ± 0.80 0.46 0.917 0.537
9. When you are with family members 2.01 ± 0.76 0.61 0.913 0.454
10. When you are in a public area 1.89 ± 0.8 0.42 0.916 0.551
11. When you are afraid of becoming dependent on them 1.82 ± 0.77 0.47 0.917 0.484
12. When you are afraid that they may affect your sexual
performance
1.81 ± 0.77 0.63 0.917 0.248
13. When the time to take them is between your meals 2.08 ± 0.68 0.65 0.912 0.475
14. When you feel that you don’t need them 1.73 ± 0.73 0.61 0.916 0.622
15. When you are traveling 1.78 ± 0.71 0.78 0.903 0.475
16. When you take them more than once a day 1.95 ± 0.72 1.00 0.916 0.370
17. If they sometimes make you feel tired 1.81 ± 0.68 0.28 0.915 0.485
18. If they sometimes makes you feel dizzy 1.81 ± 0.77 0.57 0.913 0.512
19. When you have other medications to take 2.04 ± 0.75 0.61 0.909 0.570
20. When you feel well 1.94 ± 0.83 0.55 0.917 0.665
21. If they make you want to urinate while away from the toilet 1.72 ± 0.75 0.65 0.915 0.449
How conﬁdent are you that you can carry out the following tasks?
22. Get reﬁlls for your blood pressure medications before they run
out
2.28 ± 0.75 0.84 0.915 0.517
23. Fill your prescriptions regardless of the cost 2.18 ± 0.79 0.45 0.915 0.510
24. Make your medications as part of your daily routine 2.12 ± 0.80 0.60 0.909 0.685
25. Always remember to take your blood pressure medications 2.05 ± 0.81 0.29 0.911 0.630
26. Take your blood pressure medications for the rest of your life 1.96 ± 0.83 0.47 0.916 0.472
ITC item-total scale correlation; SD standard deviation
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360 anti-hypertensive medication is a key issue in hypertension
361 management [4, 26]. Therefore, it is necessary to recognize
362 the poor self-efﬁcacy to antihypertensive medication and
363 its cause factors, in order to impose behaviour changes in
364 such patients to improve their blood pressure control.
365 The concept of adherence used in this study is ‘‘a per-
366 son’s behaviours to take anti-hypertensive medications and
367 modify their diet and/or lifestyle correspond to the rec-
368 ommendations by the clinician, according to the guideline
369 of the World Health Organization [8]. Adherence to a
370 medication regimen requires a set of behaviors that include
371 obtaining the medication, timely administration of the
372 correct dose via recommended route, and keeping up with
373 the course of the treatment. The importance of adherence to
374 medication is well accepted. However, success in keeping
375 these behaviors can be hampered by many factors related to
376 aging. The loss of sensory function, disturbances of
377memory and cognition, depression, and lifestyle changes
378due to retirement can all disrupt the routine to maintain
379regular medication [27–29]. The cessation of medication
380can lead to symptom deterioration, increased chance of
381hospitalizations, and increased morbidity and mortality
382[30, 31].
383As the adherence to anti-hypertensive therapy shall be
384considered as a precaution of cardiovascular morbidity and
385mortality, self-efﬁcacy becomes an important factor to
386assess medication adherence behaviour. However, the as-
387sociation between self-efﬁcacy and adherence to anti-hy-
388pertensive therapy has not been well-characterised in Iran.
389The current study using a Persian version of the MASE
390among Iranian patients with hypertension showed that self-
391efﬁcacy is a strong determinant of medication adherence in
392hypertensive patients, which is also closely related to their
393blood pressure control.
Table 3 Principal component analysis of the MASES
Item Factors and loading
1 2 3 4 5
1. When you are busy at home 0.673
2. When you are at work/When you are busy with daily routines 0.677
4. When you worry about taking them for the rest of your life 0.721
5. When they cause some side effects 0.703
6. When they cost a lot of money 0.702 0.493
7. When you come home late from work/when your daily works ﬁnish late 0.741
8. When you do not have symptoms 0.740
11. When you are afraid of being dependent on them 0.735
12. When you are afraid that they may affect your sexual performance 0.775
13. When the time to take them is between your meals 0.761
14. When you feel you do not need them 0.691
15. When you are traveling 0.669 0.533
16. When you take them more than once a day 0.577
19. When you have other medications to take 0.568 0.466
20. When you feel well 0.577
21. If they make you want to urinate while away from the toilet 0.677
23. Fill your prescriptions regardless of the cost 0.718 0.561
24. Make your blood pressure medications as part of your daily routine 0.729 0.603
25. Always remember to take your blood pressure medications 0.742
26. Take your blood pressure medications for the rest of your life 0.773
9. When you are with family members 0.725
10. When you are in a public area 0.633
17. If they sometimes make you feel tired 0.619 0.750
18. If they sometimes make you feel dizzy 0.730
22. Get reﬁlls for your blood pressure medications before they run out 0.759
3. When there is no one to remind you 0.655
Eigen value 11.12 1.84 1.70 1.56 1.32
% explained variance 42.76 7.09 6.55 6.00 5.41
Cumulative % explained variance 42.76 49.85 56.40 62.40 67.81
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394 The self-efﬁcacy, as stated by Bandura, is a self-belief of
395 the ability to perform some difﬁcult tasks, relevant to this
396 study: taking complicated treatment regimens [32]. This
397 can be evaluated by the questions on patient’s attitude such
398 as ‘‘I can do it’’, or in hypertensive patients ‘‘I can take my
399 anti-hypertensive medication consistently’’. The latter
400 statement has been evaluated in this study using the Persian
401MASES. Several studies have suggested the beneﬁcial ef-
402fects on health outcomes by the implementing self-efﬁcacy
403to continuing treatment programs [33, 34]. However, most
404of these studies were on life-threatening infectious dis-
405eases, such as HIV infection and chronic viral hepatitis
406[35–39]. In addition, in previous studies, self-efﬁcacy has
407been correlated with practicing self-care practices for the
Table 4 The MASES scores
between patients with
uncontrolled hypertension and




1. When you busy at home 2.54 ± 0.64 2.75 ± 0.61
2. When you are at work/When you are busy with daily routines 2.11 ± 0.55 2.31 ± 0.82
3. When there is no one to remind you 2.83 ± 0.81 3.00 ± 0.00
4. When you worry about taking them for the rest of your life 2.66 ± 0.46 2.87 ± 0.58
5. When they cause some side effects 2.43 ± 0.49 2.79 ± 0.71
6. When they cost a lot of money 2.37 ± 0.87 2.54 ± 0.81
7. When you come home late from work/when your work ﬁnishes late 2.23 ± 0.87 2.21 ± 0.55
8. When you do not have symptoms 2.36 ± 0.78 2.77 ± 0.63
9. When you are with family members 2.75 ± 0.60 2.75 ± 0.90
10. When you are in a public area 2.42 ± 0.57 2.80 ± 0.54
11. When you are afraid of becoming dependent on them 2.77 ± 0.90 3.00 ± 0.00
12. When you are afraid they may affect your sexual performance 2.39 ± 0.82 2.21 ± 0.93
13. When the time to take them is between your meals 2.55 ± 0.64 2.76 ± 0.62
14. When you feel you do not need them 2.63 ± 0.63 2.82 ± 0.92
15. When you are traveling 2.41 ± 0.84 2.62 ± 0.76
16. When you take them more than once a day 2.52 ± 0.67 2.54 ± 0.70
17. If they sometimes make you tired 2.21 ± 0.99 2.38 ± 0.00
18. If they sometimes makes you feel dizzy 1.98 ± 0.53 1.83 ± 0.78
19. When you have other medications to take 2.51 ± 0.80 2.50 ± 0.63
20. When you feel well 2.43 ± 0.76 2.64 ± 0.73
21. If they make you want to urinate while away from the toilet 2.33 ± 0.60 2.12 ± 0.95
22. Get reﬁlls for your blood pressure medications before they run out 2.60 ± 0.49 2.44 ± 0.84
23. Fill your prescriptions regardless of the cost 2.46 ± 0.54 2.63 ± 0.66
24. Make your blood pressure medications as part of your daily routine 2.81 ± 0.73 2.76 ± 0.62
25. Always remember to take your blood pressure medications 2.50 ± 0.78 2.42 ± 0.95
26. Take your blood pressure medications for the rest of your life 2.71 ± 0.81 2.67 ± 0.66
Table 5 Patients’ self-efﬁcacy
score for medication adherence
related to blood pressure
MASES-T
N Total score Average score of each item P value
Systolic blood pressure
Normal (\120 mmHg) 51 68.4 ± 8.2 2.62 H value 10.280
Pre-hypertension (120–139 mmHg) 43 64.9 ± 7.1 2.57 P = 0.006
Hypertension (C140 mmHg) 90 62.2 ± 7.5 2.50
Diastolic blood pressure
Normal (\80 mmHg) 98 67.5 ± 9.2 2.59 H value 7.125
Pre-hypertension (80–89 mmHg) 65 64.8 ± 8.6 2.53 P = 0.028
Hypertension (C90 mmHg) 21 60.3 ± 8.4 2.47
H statistic (Kruskal Wallis variance analysis)
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408 other chronic conditions [40, 41]. This study demonstrated
409 the signiﬁcant role of self-efﬁcacy in treatment adherence
410 among hypertensive patients, with similar ﬁnding as the
411 previous studies [18, 42].
412 The ﬁndings of our study obtained from the Principal
413 Component Analysis suggested a structure of one-single
414 factor of the questionnaire. Although a 5-factor structure
415 was yielded, the Factor 1 is the dominant one, and the other
416 four factors could also be easily loaded onto factor 1. Thus
417 the unidimensionality of the Persian MASE is consistent
418 with the previous studies using the English MASES [9, 17,
419 18]. Ideally, at least 100–200 patients are required for the
420 Factor Analysis [43]. In our study, 189 patients par-
421 ticipated, which makes the analysis result acceptable to
422 validate the MASES. This was further conﬁrmed by the
423 comparison between the patients with controlled and un-
424 controlled blood pressure. In this study, high value of
425 Cronbach’s alpha test was recognized and thus the item
426 redundancy was assessed. Although, several items were
427 closely correlated to each other, there was no redundancy
428 in the other items. This is because that each item refers to
429 different situation, all of which are essential to evaluate the
430 attitude towards self-efﬁcacy and practice. The high in-
431 ternal consistency in this study suggests the reliability of
432 the questionnaire. Many currently available scales from the
433 other language focus on patient’s self-esteem or self-report
434 on the empowerment to take prescribed medication re-
435 gardless of patient’s concerns [37, 44]. Therefore, the
436 Persian MASES may offer a more holistic approach to
437 determine the self-efﬁcacy in medication adherence than
438 the other measures due to the recognition of the patient’s
439 perception towards medications.
440 Moreover, based on the present and previous studies,
441 this MASES can distinguish the self-efﬁcacy between hy-
442 pertensive patients with controlled and uncontrolled blood
443 pressure. Therefore, it can be used as a tool for the clin-
444 icians to monitor their patients’ conﬁdence of using anti-
445 hypertensive medications. If the patients know little about
446 their health situation and the beneﬁt of the medications,
447 they are less likely to comply to their medications [45].
448 Therefore, MASES can be a good tool to assess the ef-
449 fectiveness of the interventions to reinforce medical
450 knowledge in the patients, in order to increase the self-
451 efﬁcacy of the patients to medication adherence [17]. In
452 our study, the patients with uncontrolled hypertension had
453 signiﬁcantly lower self-efﬁcacy than those with well con-
454 trolled blood pressure, which is similar to a previous study
455 in patients with hypertensive histories for more than one
456 year, but not newly diagnosed patients [46]. It has been
457 suggested that the longer duration of the disease could
458 contribute to a higher level of self-efﬁcacy.
459 There are still some limitations in this study. Firstly,
460 Convenience Sampling was used which may affect the
461generality of the results. Further research is needed to use
462random sampling in a larger scale including participants
463from multiple health centers in Iran. Secondly, our study
464relied on self-reporting, where certain biases of the patients
465may affect the ﬁnal results [47]. Therefore, alternative
466options, such as electronic monitors or more objective re-
467ports from the carers, are needed to achieve more accurate
468information on medication adherence. Finally, the MASES
469only questioned the current beliefs on medication adher-
470ence, where it does not reﬂect the medical adherence in the
471past, which may also affect the overall blood pressure
472control.
4735 Conclusion
474The Persian MASES is useful to improve the evaluation of
475conﬁdence in medication adherence among patients with
476hypertension. Thus, it can be used as a practical tool to
477assess the self-efﬁcacy among Iranian patients with hy-
478pertension in medical practice, clinical studies, or clinical
479trials.
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